Diabetic Neuropathic Pain Treatment Landscape 2024: Comprehensive Insights About 10+ Companies and 12+ Pipeline Drugs - Product Type, Stage, Route of Administration, and Molecule Type
July 01, 2024 07:38 ET
|
Research and Markets
Dublin, July 01, 2024 (GLOBE NEWSWIRE) -- The "Diabetic Neuropathic Pain - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.This "Diabetic Neuropathic...
Diabetic Neuropathic Pain Market to Proliferate, Assesses DelveInsight | Key Companies Active in the Domain - AstraZeneca, Eli Lilly and Company, Eisai, Helixmith, Lexicon, NeurogesX, Centrexion, Pure Green Pharmaceuticals
May 04, 2023 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, May 04, 2023 (GLOBE NEWSWIRE) -- Diabetic Neuropathic Pain Market to Proliferate, Assesses DelveInsight | Key Companies Active in the Domain - AstraZeneca, Eli Lilly and Company,...
Trevena Reports Second Quarter 2021 Results
August 12, 2021 07:00 ET
|
Trevena Inc.
Company reaffirms YE goal of 100 formulary wins OLINVYK respiratory physiology study currently enrolling, topline data expected by YE 2021 NIH / Vanderbilt University Medical Center-led...
Trevena Reports First Quarter 2021 Results
May 06, 2021 07:00 ET
|
Trevena Inc.
-- Company reaffirms YE target of 100 formulary approvals for OLINVYK® Announces new OLINVYK clinical outcomes study to further examine potential benefit on respiratory, GI, and...